Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tibulizumab - Eli Lilly and Company

Next Previous
Drug Profile

Tibulizumab - Eli Lilly and Company

Alternative Names: Anti-BAFF IL-17A monoclonal antibody - Eli Lilly and Company; BAFF/IL-17A-Eli-Lilly and Company; LY-3090106; ZB-106

Latest Information Update: 18 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antirheumatics; Bispecific antibodies; Small molecules
  • Mechanism of Action B cell activating factor inhibitors; Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 14 Aug 2023 Zura Bio plans a phase II trial for Hidradenitis-suppurativa in the second half of 2024
  • 06 Jun 2023 Zura Bio plans a phase II trial for Hidradenitis Suppurativa
  • 27 Apr 2023 Zura Bio plans a phase II trial for Systemic Sclerosis (SC), in the second half of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top